Neuroendocrine Tumors, Pancreas Neoplasm
Conditions
Keywords
portal vein resection, pancreatic surgery
Brief summary
The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific interest in the management of PanNENs and with experience on vascular reconstruction. Unlike previous studies on pancreatic cancer, it is more difficult to standardise the comparative parameters as the definition of borderline resectable disease has never been published for PanNENs. Similarly, different histological classifications make impossible to collect data exclusively on T3 tumours. Therefore, we aim to compare the short and long-term outcomes (including the impact of the histological depth of vascular invasion on survival) between patients undergoing standard PD and PD with portal vein resection for PanNENs, (regardless of T stage), by collecting and analysing retrospective data in this single centre study
Interventions
PROCEDUREPortal vein resection / reconstruction
Portal vein resection and reconstruction, with or without concommitant arterial resection
Sponsors
Royal Free Hospital NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
All patients undergoing pancreaticoduodenectomy (Whipple's or Pylorus Preserving Pancreaticoduodenectomy) for sporadic PanNENs of the head of the pancreas of any stage (R0 or R1 resections) operated from 1st January 2007 up to 31st December 2016 inclusive.
Exclusion criteria
* Multiple Neuroendocrine Neoplasia (MEN) syndrome or other genetic background * Age \<18 years old * Total pancreatectomy or different operation rather than PD * R2 Resections
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival | total of 2 years retrospective follow up | Time from surgery to disease progression, or death or completion of follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Morbidity and mortality rate | total of 2 years retrospective follow up | Postoperative morbidity and mortality |
| Histology predictive value | total of 2 years retrospective follow up | Predictive value of histologically proven invasion of the portal vein adventitia |
Contacts
Primary ContactPanagis M Lykoudis, MD, MSc
Backup ContactGiuseppe K Fusai, MD MS
Outcome results
None listed